Hikma Pharmaceuticals Plc Transaction in Own Shares (7526M)

TIDMHIK

RNS Number : 7526M

Hikma Pharmaceuticals Plc

29 August 2013

Hikma Pharmaceuticals PLC

Transaction in Own Shares

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (the "Company") announces that on 28 August 2013 it purchased 175,000 of its ordinary shares of GBP0.10 each at an average price of GBP10.11 per share (the "Share Buy-Back").

The highest price paid for a share was GBP10.14 and the lowest price paid for a share was GBP10.07.

The shares purchased pursuant to the Share Buy-Back will be held as treasury shares.

Following the Share Buy-Back the Company holds a total of 175,000 ordinary shares of GBP0.10 each as treasury shares and has 197,767,128 ordinary shares of GBP0.10 each in issue (excluding those shares held as treasury shares).

Any shares purchased under the Share Buy-back will count towards the Company's general buy-back authority of approximately 10% of the Company's issued share capital (aggregate nominal amount equal to GBP1,974,844), as approved at the Company's Annual General Meeting on 16 May 2013.

The total number of voting rights in the Company, excluding treasury shares, as at 29 August 2013 is 197,767,128. This figure may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

- ENDS -

Enquiries

 
 Hikma Pharmaceuticals PLC 
===========================  ================= 
 Peter Speirs 
  Company Secretary           +44 20 7399 2760 
===========================  =================

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

POSBKLFLXVFBBBZ

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024